Susumu Takeuchi
Overview
Explore the profile of Susumu Takeuchi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
434
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Iso H, Miyanaga A, Sato Y, Shirakura Y, Shinbu K, Inoue T, et al.
J Thorac Dis
. 2025 Mar;
17(2):687-694.
PMID: 40083503
Background: Managing malignant pleural effusion (MPE) with pleurodesis is essential for symptom relief and minimizing the need for repeated thoracentesis. Interstitial lung disease (ILD) is one of the most common...
2.
Matsumoto M, Minegishi Y, Higa K, Fukuizumi A, Onda N, Takeuchi S, et al.
BMC Pulm Med
. 2025 Jan;
25(1):9.
PMID: 39780119
Background: Acute exacerbation (AEx) of interstitial pneumonia is the most common lethal adverse event related to the pharmacological treatment of patients with lung cancer complicated with interstitial pneumonia. Although small...
3.
Hayashi A, Kamio K, Miyanaga A, Yoshida K, Noro R, Matsuda K, et al.
Anticancer Res
. 2024 Dec;
44(12):5271-5282.
PMID: 39626921
Background/aim: Chemoresistance to paclitaxel (PTX) significantly ameliorates therapeutic efficacy in patients with non-small cell lung cancer (NSCLC), especially in advanced stages, deteriorating the progression free and overall survival rates. One...
4.
Takeuchi S, Yoshimura A, Sofuni A, Ueda Y, Umezu T, Kuroda M, et al.
Jpn J Clin Oncol
. 2024 Sep;
54(12):1298-1305.
PMID: 39297618
Background: In recent years, as the availability of precision therapies expands, there is increasing reliance on genomic profiling assays to help identify the most appropriate treatment options for patients with...
5.
Terashima Y, Matsumoto M, Ozaki S, Nakagawa M, Nakagome S, Terasaki Y, et al.
Front Immunol
. 2024 Aug;
15:1370972.
PMID: 39206190
A 73-year-old man with lung squamous cell carcinoma was administered carboplatin + nab-paclitaxel + pembrolizumab for four cycles. Subsequently, he presented with multiple purpuras on his extremities, joint swelling on...
6.
Kato Y, Matsumoto M, Takano N, Hirao M, Matsuda K, Tozuka T, et al.
Cancer Med
. 2024 Jun;
13(12):e7393.
PMID: 38923428
Introduction: A neurotrophic tropomyosin receptor kinase (NTRK)-tyrosine kinase inhibitor (TKI) has shown dramatic efficacy against malignant tumors harboring an NTRK fusion gene. However, almost all tumors eventually acquire resistance to...
7.
Tozuka T, Noro R, Yoshida K, Takahashi S, Hirao M, Matsuda K, et al.
JTO Clin Res Rep
. 2024 Apr;
5(4):100668.
PMID: 38646155
Introduction: Osimertinib is a standard treatment for patients with -mutant NSCLC. Although some osimertinib resistance mechanisms have been identified, nearly 50% of the mechanisms remain to be elucidated. This study...
8.
Watanabe S, Furuya N, Nakamura A, Shiihara J, Nakachi I, Tanaka H, et al.
Eur J Cancer
. 2023 Dec;
197:113469.
PMID: 38061214
Introduction: Treatment options for patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) after EGFR-tyrosine kinase inhibitor (TKI) treatment failure are limited. An exploratory analysis of 26...
9.
Terashima Y, Matsumoto M, Iida H, Takashima S, Fukuizumi A, Takeuchi S, et al.
JTO Clin Res Rep
. 2023 Oct;
4(11):100578.
PMID: 37885809
Introduction: Pervious studies reported the association of TTF-1 expression with the efficacy of platinum-doublet chemotherapy in combination with immune checkpoint inhibitors in advanced nonsquamous NSCLC. Nevertheless, the predictive value of...
10.
Tozuka T, Noro R, Miyanaga A, Nakamichi S, Takeuchi S, Matsumoto M, et al.
Cancer Med
. 2023 Sep;
12(17):17731-17739.
PMID: 37691552
Background: The epidermal growth factor receptor (EGFR) mutation is a risk factor associated with brain metastases (BMs) in patients with non-small cell lung cancer (NSCLC). This study aimed to evaluate...